Indiana University (IU) Clinical Center for Chronic Pancreatitis Clinical Research Network

印第安纳大学 (IU) 慢性胰腺炎临床中心临床研究网络

• 批准号: 10475909
• 负责人: Evan L Fogel
• 金额: $ 9万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2022-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10475909
• 关键词: Abdominal Pain; Acute; Administrative Supplement; Adult; Biological; Child; Childhood; Clinical; Clinical Research; Diabetes Mellitus; Disease; Disease Progression; Endocrine; Enrollment; Epidemiology; Exocrine pancreas; Functional disorder; Funding; Goals; Health Care Costs; Hormonal; Indiana; Individual; Longitudinal Studies; Malignant neoplasm of pancreas; Non-Insulin-Dependent Diabetes Mellitus; Onset of illness; Patients; Population; Progressive Disease; Research Personnel; Resources; Risk; Risk Factors; Secondary to; Testing; Universities; Work; biomedical referral center; blood glucose regulation; candidate marker; chronic pain; chronic pancreatitis; clinical center; design; early onset; experience; genetic variant; insight; member; predictive test; profiles in patients; recruit; response

Chronic pancreatitis (CP) is a progressive disease, often leading to loss of exocrine and endocrine function and debilitating abdominal pain; it is unknown why some individuals progress and develop complications, including pancreatogenic diabetes (T3cDM) and/or pancreas cancer (PDAC). In the Consortium for the study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC), initially formed in 2015, investigators have proposed and initiated several well-powered studies of risk factors, environmental influences, and proof-of-concept studies to move the field forward, particularly those factors that increase the risk of T3cDM and PDAC. In the second cycle of the CPDPC, this administrative supplement will allow for ongoing recruitment and retention of subjects in two of the CPDPC's high-priority longitudinal studies, namely PROCEED and INSPPIRE 2, as well as DETECT, designed to better define and characterize T3cDM.

慢性胰腺炎（CP）是一种进行性疾病，通常导致外分泌和内分泌功能的丧失以及 使腹痛使人衰弱；尚不清楚为什么有些人会发展并发展并发症，包括 胰腺生成糖尿病（T3CDM）和/或胰腺癌（PDAC）。在慢性研究的联盟中 胰腺炎，糖尿病和胰腺癌（CPDPC）最初成立于2015年，研究人员提出了 并开始了几项有关风险因素，环境影响和概念验证研究的驱动力量的研究 向前迈进，尤其是那些增加T3CDM和PDAC风险的因素。在第二个 CPDPC的周期，这种行政补充将允许持续招募和保留受试者 在CPDPC的两项高优先纵向研究中，即进行和Insppire 2，以及 检测，旨在更好地定义和表征T3CDM。